Chronic Lymphedema Model
Chronic Lymphedema Model - Related Videos
03:21
Murine Tail Lymphedema Model: An In Vivo Technique to Generate Sustained Lymphedema in Murine Tail
0 Views •
2025
This video describes an in vivo technique to generate murine tail lymphedema, an abnormal fluid accumulation in the interstitial tissue space leading to swelling in the tail. The model is applied to study mechanisms and therapy for lymphedema.
03:13
Lymphedema Ultrasonography: A Technique to Measure the Change in Thickness of an Affected Tissue
0 Views •
2023
This video utilizes ultrasonography for diagnosis and follow-up tests to determine treatment efficacy of Progressive Resistance Exercise (PRE) in breast cancer-related lymphedema (BCRL). Ultrasonography can be applied effectively to ensure diagnosis and treatment of lymphedema.
04:38
A Murine Tail Lymphedema Model
0 Views •
Cited by 20 •
2021
Lymphedema is extremity swelling caused by lymphatic dysfunction. We describe a chronic murine tail model of lymphedema and the novel use of tissue nanotransfection technology (TNT) for genetic cargo delivery to the tail.
06:28
An Obstructive Chronic Pancreatitis Model Established Through Electrocoagulation
0 Views •
2025
The present protocol describes a novel approach to modeling chronic obstructive pancreatitis, which involves visualization of the pancreatic duct and electrocoagulation of the pancreatic duct to cause pancreatic duct obstruction.
09:01
Chronic Salmonella Infected Mouse Model
0 Views •
Cited by 12 •
2010
Establish a chronic bacterial infected mouse model with persistent Salmonella typhimurium colonization in intestine for 27 weeks.
FAQs
Persistent lymphatic impairment drives more than fluid accumulation. Protein-rich interstitial fluid remains in tissue, where it promotes inflammation and initiates structural remodeling. Over time, these processes contribute to fibrosis, or buildup of scar-like tissue, and adipose deposition. A chronic lymphedema model therefore helps connect altered drainage with the progressive tissue changes that sustain disease.
Inflammation, fibrosis, and adipose deposition show that lymphatic dysfunction has produced lasting tissue remodeling rather than temporary swelling alone. These features help researchers judge whether a model reproduces chronic disease progression and whether an intervention addresses broader tissue changes. Evaluating them alongside lymphatic function provides a more complete picture of disease severity and treatment response.
The key difference is duration and the tissue response that duration permits. Short-term injury models may capture early swelling, whereas chronic lymphedema models are intended to reproduce sustained dysfunction, inflammation, fibrosis, and adipose deposition. This distinction makes chronic systems more suitable for studying long-term progression and therapies designed for persistent lymphedema.
A useful chronic lymphedema model should reproduce sustained tissue changes rather than only an early swelling response. Investigators can use it to assess lymphatic function, follow disease progression, and compare how well candidate interventions address persistent abnormalities. This criterion matters because a model that ends before remodeling develops may not reflect the therapeutic challenges of lasting lymphedema.
Studies can use the model to compare treatment strategies across different stages of chronic disease. Relevant approaches include compression, surgical repair, pharmacological treatment, and regenerative strategies. The model provides a common experimental context for examining whether an intervention can improve lymphatic dysfunction or limit associated tissue remodeling, helping support treatment development for lasting lymphedema.
Researchers select or establish a system with persistent lymphatic dysfunction, evaluate lymphatic function and tissue changes, and then assess a defined intervention. Interpretation should include the long-term features being modeled, including inflammation, fibrosis, and adipose deposition. This workflow connects treatment assessment to both disease progression and structural remodeling rather than relying on swelling as the sole outcome.
Their clinical relevance comes from representing the sustained abnormalities experienced by patients with lasting lymphedema. By supporting assessment of lymphatic function, tissue remodeling, and treatment effects, these models help researchers compare conservative, surgical, pharmacological, and regenerative approaches. They also provide a basis for determining whether a therapy addresses chronic disease features rather than only its initial fluid accumulation.